CLEAN COPY-ENTER

15. A method of preventing or alleviating pain and inflammatory processes and diseases in a member of the species Canis familiaris with reduced or no undesirable gastro-intestinal side effects normally associated with administration to said member of non-steroidal anti-inflammatory drugs, said member having been examined by a veterinarian practitioner and diagnosed as in need of such treatment using a drug which selectively inhibits inducible cyclo-oxygenase-2(COX-2) to prevent or alleviate said pain and inflammatory processes with substantially no inhibition of constitutive cyclo-oxygenase-1 (COX-1) to reduce or avoid said side effects, which comprises administering to said member of the species Canis familiaris that has been so examined and diagnosed an amount therapeutically effective to treat or prevent pain and inflammation with reduction in or avoidance of said side effects of the formula:



Formula (I)

wherein:



where A is hydroxy, (C_1 - C_4)alkoxy, amino, hydroxyamino, mono-(C_1 - C_2)alkylamino, di-(C_1 - C_2)alkylamino; X and Y are independently H or (C_1 - C_2)alkyl; and n is 1 or 2;

R^6 is halogen, (C_1 - C_3)alkyl, trifluoromethyl, or nitro;

R^9 is H; $(C_1 - C_2)$alkyl; phenyl or phenyl-$(C_1 - C_2)$alkyl, where phenyl is optionally mono-substituted by fluoro or chloro; -C(=O)-R, where R is $(C_1 - C_2)$alkyl or phenyl, optionally mono-substituted by fluoro or chloro; or -C(=O)-O-R^1 , where R^1 is $(C_1 - C_2)$alkyl;

where X and Y are different, the (-)(*R*) and (+)(*S*) enantiomers thereof; and all pharmaceutically acceptable salt forms, prodrugs and metabolites thereof which are therapeutically active for treating or preventing pain and inflammation.

16. The method according to claim 15 where the pain and inflammation is caused by osteoarthritis, the drug administered is carprofen and administration is once or twice daily oral administration of a caplet, chewable tablet, or suspension containing from 25 to 100 mg of carprofen.

17. The method according to claim 15 where the pain and inflammation is caused by osteoarthritis, the drug administered is carprofen and administration is once or twice daily by injection containing from 25 to 100 mg of carprofen.

18. A method of treating a member of the species Canis familiaris, which member has been evaluated and determined to be (1) in need of treatment to alleviate or prevent pain and inflammatory processes and diseases with reduced or no undesirable gastro-intestinal side effects normally associated with administration of non-steroidal anti-inflammatory drugs to said member and (2) said member will benefit by using such treatment from the selective inhibition of inducible cyclo-oxygenase-2 (COX-2) to prevent or alleviate said pain and inflammatory processes with little or reduced inhibition of constitutive cyclo-oxygenatse-1 (COX-1) to reduce or avoid said side effects, comprising administering to said member of the species Canis familiaris which has been so evaluated and

diagnosed an amount therapeutically effective to treat or prevent pain and inflammation of the formula:



Formula (I)

wherein:

R^2 is 

where A is hydroxy, (C_1 - C_4)alkoxy, amino, hydroxyamino, mono-(C_1 - C_2)alkylamino, di-(C_1 - C_2)alkylamino; X and Y are independently H or (C_1 - C_2)alkyl; and n is 1 or 2;

R^6 is halogen, (C_1 - C_3)alkyl, trifluoromethyl, or nitro;

R^9 is H; (C_1 - C_2)alkyl; phenyl or phenyl-(C_1 - C_2)alkyl, where phenyl is optionally mono-substituted by fluoro or chloro; -C(=O)-R, where R is (C_1 - C_2)alkyl or phenyl, optionally mono-substituted by fluoro or chloro; or -C(=O)-O-R^1 , where R^1 is (C_1 - C_2)alkyl;

where X and Y are different, the (-)(*R*) and (+)(*S*) enantiomers thereof; and all pharmaceutically acceptable salt forms, prodrugs and metabolites thereof which are therapeutically active for treating or preventing pain and inflammation.

19. The method according to claim 18 where the pain and inflammation is caused by osteoarthritis, the drug administered is carprofen and administration is once or twice daily oral administration of a caplet, chewable tablet, or suspension containing from 25 to 100 mg of carprofen.

20. The method according to claim 18 where the pain and inflammation is caused by osteoarthritis, the drug

administered is carprofen and administration is once or twice daily by injection containing from 25 to 100 mg of carprofen.

21. A method of treating a member of the species Canis familiaris to prevent or alleviate pain and inflammatory processes and diseases which comprises administering to a member of such species which has been

a) evaluated and determined by a veterinarian practitioner to be in need of such treatment with a drug which inhibits the activity of inducible cyclo-oxygenase-2(COX-2) to prevent or alleviate said pain and inflammatory processes while

(b) avoiding or reducing the gastro-intestinal side effects normally associated with administration of non-steroidal anti-inflammatory drugs to said member and therefore

(c) to benefit from treatment with a drug that does not substantially inhibit the activity of constitutive cyclo-oxygenase-1(COX-1) so that said side effects are reduced or eliminated, which method comprises administering to said member of the species Canis familiaris which has been so evaluated and determined, a therapeutically effective amount of the formula:



Formula (I)

wherein:

R^2 is 

where A is hydroxy, (C_1 - C_4)alkoxy, amino, hydroxyamino, mono-(C_1 - C_2)alkylamino, di-(C_1 - C_2)alkylamino; X and Y are independently H or (C_1 - C_2)alkyl; and n is 1 or 2;

R^6 is halogen, (C_1 - C_3)alkyl, trifluoromethyl, or nitro;

R^9 is H; (C_1 - C_2)alkyl; phenyl or phenyl-(C_1 - C_2)alkyl, where phenyl is optionally mono-substituted by fluoro or chloro; -C(=O)-R, where R is (C_1 - C_2)alkyl or phenyl, optionally mono-substituted by fluoro or chloro; or -C(=O)-O-R^1 , where R^1 is (C_1 - C_2)alkyl;

where X and Y are different, the (-)(*R*) and (+)(*S*) enantiomers thereof; and all pharmaceutically acceptable salt forms, prodrugs and metabolites thereof which are therapeutically active for treating or preventing pain and inflammation,

whereby such pain and inflammation are prevented or alleviated, said side effects are avoided or reduced and COX-2 is selectively inhibited without substantial inhibition of COX-1, the selective inhibition ratio of COX-2 to COX-1 being at least 3:1 based on ex vivo inhibition levels measured in whole blood.

22. The method according to claim 21 where the pain and inflammation is caused by osteoarthritis, the drug administered is carprofen and administration is once or twice daily oral administration of a caplet, chewable tablet, or suspension containing from 25 to 100 mg of carprofen.

23. The method according to claim 21 where the pain and inflammation is caused by osteoarthritis, the drug

administered is carprofen and administration is once or twice daily by injection containing from 25 to 100 mg of carprofen.

24. A pharmaceutical combination for treating or preventing pain and inflammatory processes and diseases associated with the activity of inducible cyclo-oxygenase-2 (COX-2) in a member of the species Canis familaris with reduced or no side effects normally associated with the inhibition of the activity of constitutive cyclo-oxygenase -1 (COX-1) comprising

(1) a pharmaceutical composition comprising

(a) a therapeutically effective amount of the formula:



Formula (I)

wherein:



where A is hydroxy, (C_1 - C_4)alkoxy, amino, hydroxyamino, mono-(C_1 - C_2)alkylamino, di-(C_1 - C_2)alkylamino; X and Y are independently H or (C_1 - C_2)alkyl; and n is 1 or 2;

R^6 is halogen, (C_1 - C_3)alkyl, trifluoromethyl, or nitro;

R^9 is H; (C_1 - C_2)alkyl; phenyl or phenyl-(C_1 - C_2)alkyl, where phenyl is optionally mono-substituted by fluoro or chloro; -C(=O)-R, where R is (C_1 - C_2)alkyl or phenyl, optionally mono-substituted by fluoro or chloro; or -C(=O)-O-R^1 , where R^1 is (C_1 - C_2)alkyl;

where X and Y are different, the (-)(*R*) and (+)(*S*) enantiomers thereof; and all pharmaceutically acceptable salt forms,

prodrugs and metabolites thereof which are therapeutically active for treating or preventing pain and inflammation, and

(b) a pharmaceutically acceptable carrier therefor, in association with

(2) printed informational material conveying that said pharmaceutical composition contains a therapeutic agent, which when administered to said member effectively inhibits the activity of COX-2 to prevent said pain and inflammatory processes and diseases while reducing or eliminating undesirable gastro-intestinal side effects by substantially avoiding inhibition of the activity of COX-1.

25. The pharmaceutical combination according to claim 24 wherein the pharmaceutical composition and printed material are packaged in association with a container.

26. A method of treating a member of the species Canis familiaris to prevent or alleviate pain and inflammatory processes and diseases which comprises

(a) evaluating said member by a veterinarian practitioner to determine if the member is in need of treatment with a drug which inhibits the activity of inducible cyclo-oxygenase-2 (COX-2),

(b) evaluating said member by a veterinarian practitioner to determine if the member would benefit from the treatment with a drug that does not substantially inhibit the activity of constitutive cyclo-oxygenase-1 (COX-1) so that gastro-intestinal side effects will be reduced or avoided,

(c) determining that said member will be benefited from the treatment with a drug that selectively inhibits the activity of COX-2 with little or no inhibition of the activity of COX-1, and

(d) administering to said member of the species Canis familiaris which has been so evaluated and determined, a therapeutically effective amount of the formula:



Formula (I)

wherein:



where A is hydroxy, (C_1 - C_4)alkoxy, amino, hydroxyamino, mono-(C_1 - C_2)alkylamino, di-(C_1 - C_2)alkylamino; X and Y are independently H or (C_1 - C_2)alkyl; and n is 1 or 2;

R^6 is halogen, (C_1 - C_3)alkyl, trifluoromethyl, or nitro;

R^9 is H; (C_1 - C_2)alkyl; phenyl or phenyl-(C_1 - C_2)alkyl, where phenyl is optionally mono-substituted by fluoro or chloro; -C(=O)-R, where R is (C_1 - C_2)alkyl or phenyl, optionally mono-substituted by fluoro or chloro; or -C(=O)-O-R^1 , where R^1 is (C_1 - C_2)alkyl;

where X and Y are different, the (-)(*R*) and (+)(*S*) enantiomers thereof; and all pharmaceutically acceptable salt forms, prodrugs and metabolites thereof which are therapeutically active for treating or preventing pain and inflammation, whereby such pain and inflammation are prevented or alleviated, said side effects are avoided or reduced and COX-2 is selectively inhibited without substantial inhibition of COX-1, the selective inhibition ratio of COX-2 to COX-1 being

at least 3:1 based on ex vivo inhibition levels measured in whole blood.